XT
RAPP

XTX Topco’s Rapport Therapeutics RAPP Stock Holding History

XTX Topco’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
47,903
+34,841
+267% +$980K 0.03% 1084
2025
Q4 		$396K Buy
+13,062
New +$361K 0.01% 1818
2025
Q2 		– Sell
-15,442
Closed -$155K – 3327
2025
Q1 		$155K Buy
+15,442
New +$200K 0.01% 1760

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

XTX Topco's RAPP Position: Q1 2026 in Review

XTX Topco increased its Rapport Therapeutics (RAPP) stake by 267% in Q1 2026, buying an estimated $980K and bringing the position to 47,903 shares worth $1.5M. The position accounts for 0.03% of the portfolio, ranked #1084.

XTX Topco first reported a position in RAPP in Q1 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • XTX Topco held 47,903 shares of Rapport Therapeutics worth $1.5M as of Q1 2026.
  • XTX Topco bought 34,841 Rapport Therapeutics shares in Q1 2026, an estimated $980K.
  • Rapport Therapeutics made up 0.03% of XTX Topco's portfolio in Q1 2026, its #1084 holding.
  • XTX Topco first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.